MiddleBrook brings in Morgan Stanley for review

MiddleBrook Pharmaceuticals has brought in Morgan Stanley to advise the company on its strategic alternatives, including a possible sale of the company. MiddleBrook, which develops anti-infectives, says the review will cover everything from staying on its present course to inking new collaborations and selling assets. Executives of the developer--formerly known as Advancis--first announced the company was undergoing a strategic review last spring. The FDA approved its resubmitted application for a strep throat remedy in January.

- see MiddleBrook's release
- read the AFX story

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.